Starling Oncology, Inc. - 8-K Filing
Starling Oncology provides FY26 revenue guidance of $650M–$660M and reports 3Q26 revenue of $170M, a 24% YoY increase.
Tickers: $DFPH
More Regulatory news
- Gores Holdings XI, Inc. - 10-Q Filing
- Peraso Inc. - 8-K Filing
- SOLESENCE, INC. - 10-Q Filing
- BioRestorative Therapies, Inc. - 8-K Filing
- Jaws Mustang Acquisition Corp - 10-Q Filing
- Private Bancorp of America, Inc. - 10-Q Filing
- USA Rare Earth, Inc. - 10-Q Filing
- SCHWAB CHARLES CORP - 8-K Filing
- SPRUCE POWER HOLDING CORP - 8-K Filing
- Xterax Corp II - 10-Q Filing